Milestone! World's First Ovarian Dual Activation Technology Assists Patients in Conception
Release time:
2025-01-15
Recently, a major breakthrough in the field of reproductive health has garnered wide attention. The "ovarian dual activation" technology, collaboratively developed by the Yinfeng Life Sciences Research Institute (referred to as "Yinfeng Life Sciences") and the team of Professor Wang Huiying and Dr. Jin Bo from the Shenzhen Hospital of Beijing University of Chinese Medicine (referred to as "the hospital"), has achieved another milestone in cryobiomedical technology. Using methods of "cryopreservation + PFC", this technology has helped two patients achieve natural conception, providing new hope for women of childbearing age who are cancer patients, infertile, or of advanced maternal age.
This is reportedly the first global instance of using this method for ovarian activation and achieving successful natural conception. The application of this technology not only brings blessings to patients with premature ovarian insufficiency and infertility but also offers a novel solution for preserving the fertility of female cancer patients of childbearing age. In China, at least one million children and women of childbearing age face the risk of iatrogenic premature ovarian insufficiency annually. Currently, ovarian tissue cryopreservation and transplantation are regarded as one of the most promising fertility preservation methods internationally.
World's First Ovarian Dual Activation Technology Assists Two Patients in Natural Conception
The team innovatively combined the in vitro cryo-activation technology (IVA) of primordial follicles with the platelet-free plasma (PFC) technology extracted from autologous veins, providing a safer, more effective, and personalized treatment solution for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
Traditional IVA technology processes ovarian tissues externally using drug or non-drug methods; however, it presents issues like damaging primordial follicle DNA, low safety, and activation efficiency. The Yinfeng Life Sciences along with the team led by Wang Huiying and Jin Bo from the hospital applied several innovative technologies, adopting in vitro vitrification cryo-activation of ovarian tissues combined with the dual activation of PFC, establishing a new, safe, and effective technology for activating primordial follicles.
PFC technology employs special methods to concentrate, activate, and separate various growth factors, cytokines, and related proteins from autologous venous blood, followed by freeze-drying and other standardized preparation processes. Clinical studies have proven these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, follicles in the ovaries are difficult to activate and grow using traditional methods. The team's innovative IVA technology involves taking a small piece of ovarian cortical tissue via laparoscopic surgery, employing low-temperature cryo-revival technology for low-temperature activation processing in the laboratory. About an hour later, the tissue is transplanted in situ, making the previously atrophied ovarian tissue soft and supple again. Postoperative assessments showed improvements in ovarian volume, follicle count, and ovarian arterial blood flow, with hormone levels returning to normal.
Currently, the team has performed PFC ovarian activation on over 300 POI/POR patients and conducted data analyses on 11 cases of ovarian tissue cryo-activation technology. Results indicated the technology significantly improved ovarian function in patients, activated dormant follicles, and partially restored fertility. Among the 11 cases of ovarian tissue cryo-activation transplantation, two patients successfully achieved natural conception after three months of treatment.
Ovarian Cryo-Activation: Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual activation technology not only provides a safe and reliable new technology for POI/POR patients but also offers options for fertility preservation in cancer patients.
Fertility preservation, in essence, is a comprehensive solution integrating surgery, drugs, and laboratory technologies, aiming to protect human reproductive capabilities and ensure the continuous inheritance of genetic information. For women, fertility preservation mainly covers oocyte freezing, embryo freezing, and ovarian tissue freezing techniques. For men, sperm freezing is the main method to preserve fertility. Ovarian tissue cryopreservation and transplantation are currently seen as the most promising fertility preservation methods internationally, serving as the sole fertility preservation method for prepubescent girls and women of childbearing age who cannot delay cancer treatment.
The technology also shows potential for application in menopause management. By preserving part of the ovarian tissue at a young age through deep cryogenic preservation and transplanting it at an older age, menopause can be delayed, substituting hormone treatments and helping to slow down aging.
In the future, Yinfeng Life Sciences will collaborate with the Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang) to continue original technological research in "fertility preservation technology," aiming to establish a complete and comprehensive fertility preservation system, extensively and effectively applying cryopreservation technology in clinical fertility preservation, contributing to building a fertility-friendly society.
We have reason to believe that cryobiomedical technology will become increasingly mature in larger scales, involving more complex organs and complete life forms. Whether in terms of "walking upright" in time or future Mars colonization, the development prospects of cryobiomedical technology deserve our shared anticipation.
Latest developments
Recently, the "Novel Technology for Ultra-Low Temperature Cryopreservation, Activation, and Transplantation of Human Ovarian Tissue," developed through a collaborative effort between Shandong Yinfeng Life Science Research Institute and Beijing University of Chinese Medicine Shenzhen Hospital, has been awarded the 2025 Shandong Refrigeration and Air Conditioning Science and Technology Award. This groundbreaking technology pioneers a new pathway for female fertility preservation, marking a significant leap in China’s interdisciplinary advancements in reproductive medicine and cryobiology.
On May 19, a delegation from the Chinese Training Workshop for Government Officials of Developing Countries visited the exhibition hall of Yinfeng Biological Group's Cryomedicine Research Center. Government officials from multiple countries gained in-depth insights into Yinfeng’s innovative achievements in cryobiomedicine, cell storage, genetic technology, and other fields. They engaged in discussions with the delegation on technology transfer and international cooperation, contributing to the building of a global community with a shared future for humanity.
On the morning of May 17, 2025, an immersive exploration into life sciences and cryomedicine concluded successfully at Jinan Yinfeng Biological Science Park. Hosted by the Shandong Yinfeng Life Science Research Institute, this event offered members a firsthand look into the research base through activities such as ultra-low temperature cryotherapy experiences, brainwave signal acquisition system trials, and expert panel discussions. Participants witnessed the infinite possibilities that cryogenic technology and life sciences hold for humanity.
The international academic platform ScholarGPS recently announced its global lists of Highly Ranked Scholars - Lifetime and Highly Ranked Scholars - Prior 5 Years, recognizing the top 0.05% of scholars across various disciplines. Among the selected Chinese scholars are national-level talents, leading figures in specialized fields, and seasoned academics dedicated to long-term research.
In January 2025, members of the Yinfeng cryomedicine team actively participated in the "Sino-French Aerial Emergency Medical Rescue Training" and obtained certification. This signifies a further enhancement of the team's professional capabilities in the field of international emergency medical rescue.
Brands are an important symbol of high-quality development. Under the drive of strategies such as Brand Strong Province and Good Products Shandong, Shandong brands have risen to prominence. Particularly in recent years, Shandong brands have focused on new quality productivity, using "new" to enhance quality, achieving remarkable results in high-quality development.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
